RxDoctor Payments DataLook up a doctor →

Shannon Fryery, NP

Family · Oxford, MSNPI 1407895725

Payments from drug & device makers

$126,766in general payments, 2019–2025

Across 715 payments — averaging $177.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$120K
  • Viiv Healthcare Company$2K
  • Merck$934
  • AbbVie$866
  • Theratechnologies Inc.$826
  • Insmed, Inc.$674
  • plus $1K from 7 others

What the payments were for

  • Consulting fees$5,4804%
  • Speaking & faculty fees$86,12668%
  • Travel & lodging$21,29117%
  • Food & beverage$13,69111%
  • Education$1790%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,766 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$51,448
Medicare patients
254
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala535$2,133,910
JulucaDolutegravir/Rilpivirine127$448,017
CabenuvaCabotegravir/Rilpivirine57$375,244
DovatoDolutegravir Sodium/Lamivudine93$287,171
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf47$218,009
TrogarzoIbalizumab-Uiyk16$104,798
Daptomycin21$33,750
DescovyEmtricitabine/Tenofov Alafenam13$28,167
JanuviaSitagliptin Phosphate35$19,808
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium16$15,223
Voriconazole27$10,851
SymbicortBudesonide/Formoterol Fumarate23$4,514
Doxycycline Hyclate150$3,815
ErtapenemErtapenem Sodium12$3,785
Rifampin40$3,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$119,711$2,162,077548 claims
Viiv Healthcare CompanyJuluca, Cabenuva, Dovato$2,397$1,110,432277 claims
Theratechnologies Inc.Trogarzo$826$104,79816 claims
MerckJanuvia$934$19,80835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →